Colistin: New lessons on an old antibiotic

Clinical Microbiology and Infection

Volumn 18, Issue 1, 2012, Pages 18-29

  Yahav, D ^a,b   Farbman, L ^a,b   Leibovici, L ^a,b   Paul, M ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Colistin; Multidrug resistant bacteria; Nephrotoxicity; Polymyxins; Ventilator associated pneumonia

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIBIOTIC AGENT; BACTERIAL ENZYME; BETA LACTAM; CARBAPENEM; COLISTIMETHATE; COLISTIN; COLISTINASE; GLYCOPEPTIDE; IMIPENEM; MEROPENEM; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYMYXIN; POLYMYXIN B; RIFAMPICIN; SULBACTAM; UNCLASSIFIED DRUG; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ALLERGIC PNEUMONITIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL SKIN DISEASE; BACTERICIDAL ACTIVITY; BLOOD BRAIN BARRIER; BRAIN VENTRICULITIS; BRONCHOSPASM; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL (TOPIC); CRITICALLY ILL PATIENT; CYSTIC FIBROSIS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG PENETRATION; DRUG POTENTIATION; DRUG WITHDRAWAL; ENTEROBACTERIACEAE INFECTION; GRAM NEGATIVE BACTERIUM; HEMOPERFUSION; HUMAN; INFECTION; KIDNEY FAILURE; KLEBSIELLA PNEUMONIAE; MAXIMUM PLASMA CONCENTRATION; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NEUROMUSCULAR BLOCKING; NEUROTOXICITY; PAENIBACILLUS POLYMYXA; PAENIBACILLUS POLYMYXA SUBSPECIE COLISTINUS; PLEURA FLUID; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SEIZURE; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; STENOTROPHOMONAS MALTOPHILIA; SYNOVIAL FLUID; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 83655164078     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03734.x     Document Type: Review

References (140)

1. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-1341.
2. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45: 781-785.
3. Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009; 22: 535-543.
4. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72: 857-868.
5. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
6. Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related peptide antibiotics. Annu Rev Biochem 1977; 46: 723-763.
7. Hancock RE, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother 1999; 43: 1317-1323.
8. Velkov T, Thompson PE, Nation RL, Li J. Structure-activity relationships of polymyxin antibiotics. J Med Chem 2010; 53: 1898-1916.
9. Zhang L, Dhillon P, Yan H, Farmer S, Hancock RE. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 3317-3321.
10. Peterson AA, Hancock RE, McGroarty EJ. Binding of polycationic antibiotics and polyamines to lipopolysaccharides of Pseudomonas aeruginosa. J Bacteriol 1985; 164: 1256-1261.
11. Newton BA. The properties and mode of action of the polymyxins. Bacteriol Rev 1956; 20: 14-27.
12. Hale JD, Hancock RE. Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev Anti Infect Ther 2007; 5: 951-959.
13. Mogi T, Kita K. Gramicidin S and polymyxins: the revival of cationic cyclic peptide antibiotics. Cell Mol Life Sci 2009; 66: 3821-3826.
14. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005; 3: 238-250.
15. Rogers MJ, Cohen J. Comparison of the binding of gram-negative bacterial endotoxin by polymyxin B sulphate, colistin sulphate and colistin sulphomethate sodium. Infection 1986; 14: 79-81.
16. FDA. Coly-Mycin® M Parenteral, (Colistimethate for Injection, USP). NDA 50-108/S-026 [serial on the Internet]. Available at: (last accessed 1 December 2011).
17. Walkty A, DeCorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of colistin (polymyxin E) against 3, 480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008. Antimicrob Agents Chemother 2009; 53: 4924-4926.
18. European Committee on Antimicrobial Susceptibility Testing (EUCAST). European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 13, 5 January 2011 [serial on the Internet] 2011. Available at: (last accessed 1 December 2011).
19. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-First Informational Supplement [serial on the Internet]. Wayne, PA: CLSI, 2011. Available at: (last accessed 1 December 2011).
20. Li J, Nation RL, Turnidge JD et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
21. Ko KS, Suh JY, Kwon KT et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 2007; 60: 1163-1167.
22. Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 2008; 52: 351-352.
23. Li J, Rayner CR, Nation RL et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50: 2946-2950.
24. Yau W, Owen RJ, Poudyal A et al. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect 2009; 58: 138-144.
25. Meletis G, Tzampaz E, Sianou E, Tzavaras I, Sofianou D. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother 2011; 66: 946-947.
26. Poudyal A, Howden BP, Bell JM et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2008; 62: 1311-1318.
27. Bergen PJ, Forrest A, Bulitta JB et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother 2011; 55: 5134-5142.
28. Antoniadou A, Kontopidou F, Poulakou G et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 2007; 59: 786-790.
29. Matthaiou DK, Michalopoulos A, Rafailidis PI et al. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med 2008; 36: 807-811.
30. Lee JY, Song JH, Ko KS. Identification of nonclonal Pseudomonas aeruginosa isolates with reduced colistin susceptibility in Korea. Microb Drug Resist 2011; 17: 299-304.
31. Sun HY, Fujitani S, Quintiliani R, Yu VL. Pneumonia due to Pseudomonas aeruginosa: Part II: Antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy. Chest 2011; 139: 1172-1185.
32. Johansen HK, Moskowitz SM, Ciofu O, Pressler T, Hoiby N. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros 2008; 7: 391-397.
33. Park YK, Choi JY, Shin D, Ko KS. Correlation between overexpression and amino acid substitution of the PmrAB locus and colistin resistance in Acinetobacter baumannii. Int J Antimicrob Agents 2011; 37: 525-530.
34. Bengoechea JA, Skurnik M. Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in Yersinia. Mol Microbiol 2000; 37: 67-80.
35. Moffatt JH, Harper M, Harrison P et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010; 54: 4971-4977.
36. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50: 1953-1958.
37. Barnett M, Bushby SR, Wilkinson S. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol Chemother 1964; 23: 552-574.
38. Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob Agents Chemother 2008; 52: 3047-3051.
39. The European Agency for the Evaluation of Medicinal Products. Veterinary medicines and inspections. Colistin: summary report. EMEA/MRL/016/95-Final. London, UK: The European Agency for the Evaluation of Medicinal Products, 2002. Available at: (last accessed 1 December 2011).
40. Falagas ME, Kasiakou SK. Use of international units when dosing colistin will help decrease confusion related to various formulations of the drug around the world. Antimicrob Agents Chemother 2006; 50: 2274-2275.
41. Li J, Nation RL, Turnidge JD. Defining the dosage units for colistin methanesulfonate: urgent need for international harmonization. Antimicrob Agents Chemother 2006; 50: 4231; author reply 2.
42. Couet W, Gregoire N, Marchand S, Mimoz O. Colistin pharmacokinetics: the fog is lifting. Clin Microbiol Infect 2012; 18: 30-39.
43. Markantonis SL, Markou N, Fousteri M et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother 2009; 53: 4907-4910.
44. Everett ED, Strausbaugh LJ. Antimicrobial agents and the central nervous system. Neurosurgery 1980; 6: 691-714.
45. Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ, Martin-Lozano D, Prados T, Pachon J. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 2002; 21: 212-214.
46. Antachopoulos C, Karvanen M, Iosifidis E et al. Serum and cerebrospinal fluid levels of colistin in pediatric patients. Antimicrob Agents Chemother 2010; 54: 3985-3987.
47. Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection: a case series and systematic review. Clin Microbiol Infect 2009; 16: 888-894.
48. Mandell G, Bennett J, Dolin R. Principles and practice of infectious diseases, 7th edn. Philadelphia, PA: Churchill Livingstone Elsevier, 2010.
49. Imberti R, Cusato M, Villani P et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 2010; 138: 1333-1339.
50. Markou N, Fousteri M, Markantonis SL, Boutzouka E, Tsigou E, Baltopoulo G. Colistin penetration in the alveolar lining fluid of critically ill patients treated with IV colistimethate sodium. Chest 2011; 139: 232-233; author reply 3-4.
51. Optimizing Dosing of Colistin for Infections Resistant to all other Antibiotics, Approved NIH Protocol Dated 12.06.07 (DMID Protocol#07-0036). NCT00235690. Available at: (last accessed 1 December 2011).
52. Population Pharmacokinetic Study of Colistin in Patients Infected With Multiresistant Gram-negative Bacteria. NCT01060891. Available at: (last accessed 1 December 2011).
53. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005; 5: 1.
54. Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006; 25: 596-599.
55. Pintado V, San Miguel LG, Grill F et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect 2008; 56: 185-190.
56. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant gram-negative bacterial infections. Int J Antimicrob Agents 2010; 35: 297-300.
57. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 2005; 26: 504-507.
58. Hartzell JD, Neff R, Ake J et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009; 48: 1724-1728.
59. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010; 54: 4503-4505.
60. Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents 2009; 34: 434-438.
61. Ko H, Jeon M, Choo E et al. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 2011; 117: c284-c288.
62. Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. J Infect 2011; 62: 187-190.
63. Pogue JM, Lee J, Marchaim D et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53: 879-884.
64. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-R212.
65. Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-1011.
66. Falagas ME, Rafailidis PI. Nephrotoxicity of colistin: new insight into an old antibiotic. Clin Infect Dis 2009; 48: 1729-1731.
67. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006; 10: R27.
68. Nation RL, Li J. Optimizing use of colistin and polymyxin B in the critically ill. Semin Respir Crit Care Med 2007; 28: 604-614.
69. Wahby K, Chopra T, Chandrasekar P. Intravenous and inhalational colistin-induced respiratory failure. Clin Infect Dis 2010; 50: e38-e40.
70. Leong KW, Ong S, Chee HL, Lee W, Kwa AL. Hypersensitivity pneumonitis due to high-dose colistin aerosol therapy. Int J Infect Dis 2010; 14: e1018-e1019.
71. Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A. Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series. Respir Med 2009; 103: 707-713.
72. Ghannam DE, Rodriguez GH, Raad II, Safdar A. Inhaled aminoglycosides in cancer patients with ventilator-associated gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis 2009; 28: 253-259.
73. Kofteridis DP, Alexopoulou C, Valachis A et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis 2010; 51: 1238-1244.
74. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect 2010; 16: 1230-1236.
75. Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005; 41: 754-757.
76. Lin CC, Liu TC, Kuo CF, Liu CP, Lee CM. Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan. J Microbiol Immunol Infect 2010; 43: 323-331.
77. Michalopoulos A, Fotakis D, Virtzili S et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant gram-negative bacteria: a prospective study. Respir Med 2008; 102: 407-412.
78. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005; 9: R53-R59.
79. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by gram-negative bacteria. J Antimicrob Chemother 2010; 65: 2645-2649.
80. Falagas ME, Rafailidis PI, Ioannidou E et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010; 35: 194-199.
81. Paul M, Bishara J, Levcovich A et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 2010; 65: 1019-1027.
82. Souli M, Rekatsina PD, Chryssouli Z, Galani I, Giamarellou H, Kanellakopoulou K. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates? Antimicrob Agents Chemother 2009; 53: 2133-2135.
83. Tripodi MF, Durante-Mangoni E, Fortunato R, Utili R, Zarrilli R. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents 2007; 30: 537-540.
84. Pongpech P, Amornnopparattanakul S, Panapakdee S et al. Antibacterial activity of carbapenem-based combinations against multidrug-resistant Acinetobacter baumannii. J Med Assoc Thai 2010; 93: 161-171.
85. Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006; 27: 224-228.
86. Lin KH, Chuang YC, Lee SH, Yu WL. In vitro synergistic antimicrobial effect of imipenem and colistin against an isolate of multidrug-resistant Enterobacter cloacae. J Microbiol Immunol Infect 2010; 43: 317-322.
87. Urban C, Mariano N, Rahal JJ. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother 2010; 54: 2732-2734.
88. Pankuch GA, Seifert H, Appelbaum PC. Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Diagn Microbiol Infect Dis 2010; 67: 191-197.
89. Bergen PJ, Tsuji BT, Bulitta JB et al. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro PK/PD model. Antimicrob Agents Chemother 2011; 55: 5685-5695.
90. Rynn C, Wootton M, Bowker KE, Alan Holt H, Reeves DS. In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics. Clin Microbiol Infect 1999; 5: 32-36.
91. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003; 47: 905-909.
92. Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H. In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J Chemother 2003; 15: 235-238.
93. Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2001; 40: 117-120.
94. Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54: 5316-5322.
95. Wareham DW, Gordon NC, Hornsey M. In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 2011; 66: 1047-1051.
96. Tan TY, Ng LS, Tan E, Huang G. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007; 60: 421-423.
97. Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 2008; 14: 816-827.
98. Tan CH, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2007; 51: 3413-3415.
99. Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007; 59: 473-477.
100. Dudhani RV, Turnidge JD, Nation RL, Li J. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 2010; 65: 1984-1990.
101. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 3136-3146.
102. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11: 115-121.
103. Tascini C, Gemignani G, Palumbo F et al. Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant Pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis. J Chemother 2006; 18: 648-651.
104. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37: e154-e160.
105. Conway SP, Pond MN, Watson A, Etherington C, Robey HL, Goldman MH. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997; 52: 987-993.
106. Motaouakkil S, Charra B, Hachimi A et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006; 53: 274-278.
107. Bassetti M, Repetto E, Righi E et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008; 61: 417-420.
108. Colistin Versus Colistin Plus Fosfomycin for Infections Caused by MDR Acinetobacter baumannii. NCT01297894. Available at: (last accessed 1 December 2011).
109. Colistin Plus Rifampicin in MDR P. aeruginosa and A. baumanii. NCT01297855. Available at: (last accessed 1 December 2011).
110. Marcus R, Paul M, Elphick H, Leibovici L. Clinical implications of beta-lactam-aminoglycoside synergism: systematic review of randomised trials. Int J Antimicrob Agents 2011; 37: 491-503.
111. Baiocchi M, Catena V, Zago S, Badolati L, Baccarin M. Intrathecal colistin for treatment of multidrug resistant (MDR) Pseudomonas aeruginosa after neurosurgical ventriculitis. Infez Med 2010; 18: 182-186.
112. Gump WC, Walsh JW. Intrathecal colistin for treatment of highly resistant Pseudomonas ventriculitis. Case report and review of the literature. J Neurosurg 2005; 102: 915-917.
113. Quinn AL, Parada JP, Belmares J, O'Keefe JP. Intrathecal colistin and sterilization of resistant Pseudomonas aeruginosa shunt infection. Ann Pharmacother 2005; 39: 949-952.
114. Kellum JA, Uchino S. International differences in the treatment of sepsis: are they justified? JAMA 2009; 301: 2496-2497.
115. Cruz DN, Perazella MA, Bellomo R et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007; 11: R47.
116. Cruz DN, Antonelli M, Fumagalli R et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301: 2445-2452.
117. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010; 65: 1119-1125.
118. Leibovici L, Vidal L, Paul M. Aminoglycoside drugs in clinical practice: an evidence-based approach. J Antimicrob Chemother 2009; 63: 246-251.
119. Vidal L, Gafter-Gvili A, Borok S, Fraser A, Leibovici L, Paul M. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2007; 60: 247-257.
120. Leibovici L, Paul M, Poznanski O et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997; 41: 1127-1133.
121. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008; 52: 1028-1033.
122. Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010; 54: 4851-4863.
123. Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66: 1963-1971.
124. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36: 1111-1118.
125. Reina R, Estenssoro E, Saenz G et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 2005; 31: 1058-1065.
126. Kallel H, Hergafi L, Bahloul M et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007; 33: 1162-1167.
127. Hachem RY, Chemaly RF, Ahmar CA et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother 2007; 51: 1905-1911.
128. Rios FG, Luna CM, Maskin B et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J 2007; 30: 307-313.
129. Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007; 11: 402-406.
130. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 2008; 61: 1369-1375.
131. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008; 56: 432-436.
132. Gounden R, Bamford C, van Zyl-Smit R, Cohen K, Maartens G. Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis 2009; 9: 26.
133. Durakovic N, Radojcic V, Boban A et al. Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med 2011; 50: 1009-1013.
134. Lim SK, Lee SO, Choi SH et al. The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections. J Korean Med Sci 2011; 26: 325-331.
135. Kvitko CH, Rigatto MH, Moro AL, Zavascki AP. Polymyxin B versus other antimicrobials for the treatment of Pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother 2011; 66: 175-179.
136. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 2003; 47: 2659-2662.
137. Markou N, Apostolakos H, Koumoudiou C et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care 2003; 7: R78-R83.
138. Montero M, Horcajada JP, Sorli L et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection 2009; 37: 461-465.
139. Ramasubban S, Majumdar A, Das PS. Safety and efficacy of polymyxin B in multidrug resistant gram-negative severe sepsis and septic shock. Indian J Crit Care Med 2008; 12: 153-157.
140. Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect 2006; 12: 1227-1230.